- Posts:
- 0 (0 per day)
- Age:
- N/A
- Date Registered:
- May 08, 2024, 04:23:18 PM
- Local Time:
- May 20, 2024, 01:00:45 AM
- Last Active:
- May 08, 2024, 06:49:14 PM
Signature:
Finish Many of us report the next case of the patient who designed AGL secondary to be able to pembrolizumab, as well as the next situation in order t